Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

September 30, 2030

Study Completion Date

September 30, 2030

Conditions
Hepatitis BHuman Papilloma VirusGall Stones (& [Calculus - Gall Bladder])Mental Health IssueCancer LiverCancer of CervixDepression, Anxiety
Interventions
BIOLOGICAL

Gardasil 9 vaccine

Participants with a valid consent will be offered a three-dose Gardasil 9 series if eligible.

BIOLOGICAL

Hepatitis B Virus Vaccine(HBV)

Participants who do not demonstrate immunity to Hep B antibody marker in their blood, HBsAb and not HBsAg will be offered a three-dose series of Hep B. vaccine. A blood test will be done six months later to assess vaccine take i.e. immunity. Patients who demonstrate infection with Hep B virus will be referred to their doctor for further management.

BEHAVIORAL

Cognitive Behavioral Therapy

Participants who demonstrate signs and symptoms of depression and/or anxiety will be offered individual behavioral management services. This consists of weekly individual sessions by a trained therapist for 8 weeks with option for referral for further management depending on the outcome of the intervention. The positive outcome consists of a change in presenting symptoms determined after administration of the youth risk behavior screen for high school students, and PHQ-9, and Edinburgh post-natal depression screen for women respectively.

All Listed Sponsors
collaborator

National University of Science and Technology, Zimbabwe

OTHER

lead

Eunice Dube

OTHER